Influence of Fish Oil Based Intravenous Fat Emulsions on the Epidermal Barrier Function

Phase 3

Terminated

• Conditions: Intestinal Diseases
• Interventions: Drug: soybean oil (SO)-based IVFE (Medialipide); Drug: fish oil (FO)-containing IVFE (Lipidem)

• Registration Number: NCT02550860
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

The epidermal barrier efficacy is determined by the physicochemical properties of the epidermal lipid matrix, among which ω-6 essential fatty acids (EFAs) play a key role. Inversely, the ω-3 EFAs are not found in the epidermis. For patients receiving lipid-containing parenteral nutrition (LCPN), the improvement of the epidermal barrier through the infusion of most appropriate intravenous fat emulsions (IVFE) could have many applications in clinical nutrition, mainly limiting water loss in patients receiving long-term LCPN and help in electrolyte and water balance.

The objective of this interventional clinical trial is to evaluate the epidermal barrier function in patients receiving long-term LCPN comparing two compositions of IVFE: (i) soybean oil (SO)-based IVFE (Medialipide) or (ii) fish oil (FO)-containing IVFE (Lipidem). Epidermal barrier function will be assessed through the transepidermal water loss (TEWL) measurement on the skin surface, a validated marker of the epidermal barrier efficacy. The two IVFE (SO-based or FO-containing) will be compared using a randomized double blind crossover design, using patients as their own control. Each IVFE will be allocated for a 3-month period, allowing sufficient timeframe for epidermal complete renewal. Patient's epidermal and red blood cell EFA profile will be determinate in order to facilitate result interpretation.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2015-01
• Study First Submitted: 2015-08-31
• Study First Submitted QC: 2015-09-14
• Study First Posted: 2015-09-16
• Primary Completion: 2017-09-08
• Study Completion: 2017-09-08
• Status Verified: 2018-02
• Last Update Submitted: 2018-02-27
• Last Update Posted: 2018-02-28

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 13

Inclusion Criteria

• Patient with sever chronic intestinal disease requiring long term parenteral nutrition
• Receiving home lipid containing parenteral nutrition (LCPN), regardless of currently infused intravenous fat emulsion
• With a stable dose of LCPN for at least 1 month at recruitment time
• Administered at least 4 days a week through central venous access, with at least 150 mL of lipid per parenteral nutrition bag with lipid.
• Age >18
• Being available for 2 medical consultations in a 6 month period
• Who gave its written informed consent to participate to the study and without legal protection
• Social security coverage

Read More

Exclusion Criteria

• Lesser expected parenteral nutrition length than duration for the entire trial
• Dermatological criteria : History of skin disease (atopic dermatitis, psoriasis) or evolving skin disease, broken or inflamed skin on the TEWL measurement site, Use of topical creams on the TEWL measurement site, Skin or systemic allergy (asthma)
• Contraindication to one of the selected intravenous fat emulsion: Severe dyslipidemia; Uncontrolled diabetes; Sepsis; Severe hepatic impairment; Major blood clotting disorders; Egg protein, soybean, peanut or fish hyper sensibility; Serum creatinine clearance < 30 ml/min

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
soybean oil (SO)-based IVFE (Medialipide)	soybean oil (SO)-based IVFE (Medialipide)	-
fish oil (FO)-containing IVFE (Lipidem)	fish oil (FO)-containing IVFE (Lipidem)	fish oil (FO)-containing IVFE (Lipidem)

Primary Outcome Measures

Name	Time	Method
Measurement of the transepidermal water loss (TEWL).	at Day 180	Measurement will be performed in a horizontal plane on the dominant volar forearm, which is the reference site for TEWL measurement because of its low content of sebaceous glands and pilosity. The TEWL will be measured using the latest generation of closed chamber system, combined to a vapor water condenser (Aquaflux 200®), which offers the advantage of a reduced TEWL value sensitivity to ambient humidity and temperature during measurement.

Secondary Outcome Measures

Name	Time	Method
Determination of erythrocyte fatty acids ω-3	at Day 180	Essential fatty acid red blood cell monitoring more properly reflect the global membrane fatty acid composition of the body. Monitoring will be achieved at biochemistry laboratory of recruiting centers on a blood sample.
Determination of Stratum corneum (SC) ω-6	at Day 180	Stratum corneum lipids will be collected using the minimally invasive and painless "Tape Stripping" method, which consists of applying a scotch on the skin. Quantitative and qualitative composition of the SC lipid matrix will be determined using high-performance thin-layer chromatography.
Determination of erythrocyte fatty acids ω-6	at Day 180	Essential fatty acid red blood cell monitoring more properly reflect the global membrane fatty acid composition of the body. Monitoring will be achieved at biochemistry laboratory of recruiting centers on a blood sample.
Determination of Stratum corneum (SC) ω-3	at Day 180	Stratum corneum lipids will be collected using the minimally invasive and painless "Tape Stripping" method, which consists of applying a scotch on the skin. Quantitative and qualitative composition of the SC lipid matrix will be determined using high-performance thin-layer chromatography.

Trial Locations

Locations (2)

Centre Hospitalier Lyon Sud; 🇫🇷 Pierre Bénite, France

Hospices Civils de Lyon; 🇫🇷 Lyon, France